Perioperative medicine & outcomes
Assessment of Duration of Smoking Cessation Prior to Surgical Treatment of Non-small Cell Lung Cancer
Authors' conclusion
Smoking cessation at least 3 weeks prior to the surgical treatment of lung cancer is associated with reduced morbidity and mortality.
Study context
- Population
- Patients with clinical stage I non-small cell lung cancer undergoing surgical treatment, Veterans Health Administration, 2006–20166,168 (64.9%) smoking at diagnosis
- Participants
- 9,509 patients
- Exposure
- Duration of preoperative smoking cessation; quit ≥3 weeks or within 3 weeks before surgery vs nonsmokers
- Outcome
- Major complication or mortality
- Follow-up
- 30 days
Methodological detailsmultivariable restricted cubic spline functions
- Multivariable restricted cubic spline functions
Main finding
As reported in the abstract
Major complication or mortality within 30 days
Each group vs nonsmokersAdjusted odds ratio (95% CI)P value
Quit at least 3 weeks before surgery
1.005(0.702–1.437)
P = 0.98Quit within 3 weeks of surgery
1.698(1.203–2.396)
P = 0.003Observational data: associations, not effects.
Further findings
Smoking cessation before surgery among smokers at diagnosis
- Stopped smoking prior to surgery
- 662 (10.7%)
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Assessment of Duration of Smoking Cessation Prior to Surgical Treatment of Non-small Cell Lung Cancer. Ann Surg. Published 18 November 2021. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →